NDAINTRAVENOUS, SUBCUTANEOUSSOLUTION
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BORTEZOMIB (bortezomib) by Medica Corp is proteasome inhibitors [moa]. First approved in 2024.
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bortezomib is a proteasome inhibitor small molecule administered intravenously or subcutaneously as a solution. It works by blocking proteasome function to induce apoptosis in cancer cells. Approved in August 2024, it is indicated for hematologic malignancies including multiple myeloma and mantle cell lymphoma.
Growth
Early-stage commercial opportunity with moderate competitive pressure (30/100) suggests a growing team building initial market presence.
Mechanism of Action
Proteasome Inhibitors
Pharmacologic Class:
Proteasome Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Started Jan 2027
260 enrolled
Light Chain (AL) Amyloidosis
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Started Nov 2026
370 enrolled
Amyloid Light Chain (AL) Amyloidosis
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Started Oct 2026
20 enrolled
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Started Sep 2026
1,000 enrolled
Multiple Myeloma
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Started Sep 2026
500 enrolled
Multiple Myeloma
Worked on BORTEZOMIB at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.